<p>Western blot of p-ERK and total ERK in uNK cells treated with mifepristone ± cortisol. To detect p-ERK and total ERK, total cell lysates were harvested after a 30 min treatment with mifepristone (1.0 µM) ± cortisol (1.0 µM). Uterine NK cells were isolated and cultured in the medium without IL-2 for 12 h as a negative control of MAPK/ERK activation. In the drug treatment groups, uNK cells were cultured in the medium supplemented with IL-2. Uterine NK cells were cultured in the medium with IL-2 and IL-15 for 15 min as a positive control. A typical blot (A) and densitometric scans of triplicate blots (B) are shown. Data were analyzed using ANOVA and expressed as means ± SEM. *, <i>P</i><0.05.</p
RU486 (mifepristone), a glucocorticoid and progesterone receptor antagonist, has been reported to ex...
We have previously shown that the antiprogestin and antiglucocorticoid mifepristone inhibits the gro...
Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients...
<p>A, a representative immunoblot is shown after the treatment of uNK cells with mifepristone (1.0 µ...
Mifepristone (RU486), a potent antagonist of progesterone and glucocorticoids, is involved in immune...
Mifepristone (RU486), a potent antagonist of progesterone and glucocorticoids, is involved in immune...
<p>Before the treatment with cortisol ± mifepristone, uNK cells were pretreated with PD98059 (A) or ...
<p>The purified uNK cells were incubated with 0, 65, 200, and 1000 nmol/L mifepristone for 24 h. The...
<p>Isolated uNK cells were treated with cortisol (1.0 µM) ± and mifepristone (1.0 µM) for 24 h. A, a...
<p>Phosphorylated Erk (P-Erk) immunoblotting in MDA-MB-231 cells treated with or without nifedipine ...
<p>Before the treatment with cortisol ± mifepristone, uNK cells were pretreated with PD98059 (A) or ...
<p>(A) Western blot analysis to see the expression of p-MEK, MEK, p-Erk and Erk. MDA-MB 231 (left pa...
<p>(A) Cells were treated with LPS (1 µg/ml) alone or in combination with different concentrations o...
<p>(A) Expression of ERα protein in human ovarian cancer cell lines. MCF-7, a breast cancer cell lin...
<p>(A) Blocking of E2, DPN, 4OHT or G1 induced ERK1/2 phosphorylation in SUM149 cells by U0126. The ...
RU486 (mifepristone), a glucocorticoid and progesterone receptor antagonist, has been reported to ex...
We have previously shown that the antiprogestin and antiglucocorticoid mifepristone inhibits the gro...
Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients...
<p>A, a representative immunoblot is shown after the treatment of uNK cells with mifepristone (1.0 µ...
Mifepristone (RU486), a potent antagonist of progesterone and glucocorticoids, is involved in immune...
Mifepristone (RU486), a potent antagonist of progesterone and glucocorticoids, is involved in immune...
<p>Before the treatment with cortisol ± mifepristone, uNK cells were pretreated with PD98059 (A) or ...
<p>The purified uNK cells were incubated with 0, 65, 200, and 1000 nmol/L mifepristone for 24 h. The...
<p>Isolated uNK cells were treated with cortisol (1.0 µM) ± and mifepristone (1.0 µM) for 24 h. A, a...
<p>Phosphorylated Erk (P-Erk) immunoblotting in MDA-MB-231 cells treated with or without nifedipine ...
<p>Before the treatment with cortisol ± mifepristone, uNK cells were pretreated with PD98059 (A) or ...
<p>(A) Western blot analysis to see the expression of p-MEK, MEK, p-Erk and Erk. MDA-MB 231 (left pa...
<p>(A) Cells were treated with LPS (1 µg/ml) alone or in combination with different concentrations o...
<p>(A) Expression of ERα protein in human ovarian cancer cell lines. MCF-7, a breast cancer cell lin...
<p>(A) Blocking of E2, DPN, 4OHT or G1 induced ERK1/2 phosphorylation in SUM149 cells by U0126. The ...
RU486 (mifepristone), a glucocorticoid and progesterone receptor antagonist, has been reported to ex...
We have previously shown that the antiprogestin and antiglucocorticoid mifepristone inhibits the gro...
Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients...